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Abstract
Background: Monogenic defects of synaptic vesicle (SV) homeostasis have been
implicated in many neurologic diseases, including autism, epilepsy, and move-
ment disorders. In addition, abnormal vesicle exocytosis has been associated with
several endocrine dysfunctions.
Methods: We report an 11 year old girl with learning disabilities, tremors, ataxia,
transient hyperglycemia, and muscle fatigability responsive to albuterol sulfate. Fail-
ure of neuromuscular transmission was confirmed by single fiber electromyography.
Electron microscopy of motor nerve terminals revealed marked reduction in SV den-
sity, double-membrane-bound sacs containing SVs, abundant endosomes, and degen-
erative lamellar bodies. The patient underwent whole exome sequencing (WES) and
relevant sequence variants were expressed and studied in a mammalian cell line.
Results: Chromosomal microarray studies and next generation sequencing (NGS) of
mitochondrial DNA were unrevealing; however, NGS of genomic DNA showed two
rare sequence variants in the gene encoding rabphilin 3a (RPH3A). The paternally
inherited variant c.806 G>A (p.Arg269Gln) involves a substitution of a conserved
residue in the linker region, while the maternally inherited variant c.1390 G>T
(p.Val464Leu) involves a conserved amino acid substitution in the highly conserved
C2A region. Expression studies revealed that p.Arg269Gln strongly impairs the bind-
ing of rabphilin 3a to 14-3-3, which is a proposed regulator of synaptic transmission
and plasticity. In contrast, the binding of rabphilin 3a to 14-3-3 is only marginally
impaired by p.Val464Leu; thus, the pathogenic role of p.Val464Leu remains unclear.
Conclusion: In summary, we report a patient with a multisystem neurologic dis-
order and altered SV regulation attributed to defects in RPH3A, which grants fur-
ther studies of this gene in human disorders of synaptic transmission.
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1 | INTRODUCTION
Congenital myasthenic syndromes (CMS) are a diverse
group of neurologic diseases of neuromuscular transmission
that are characterized by muscle weakness and fatigability
(Engel, Shen, Selcen, & Sine, 2015). The majority of CMS
result from genes defects in proteins of the postsynaptic
compartment. However, in recent years the introduction of
whole exome sequencing (WES) into clinical practice has
allowed the discovery of many rare forms of CMS due to
defects in genes encoding proteins of the presynaptic appa-
ratus. Most of these newly described presynaptic CMS are
caused by defects in proteins associated with the SNARE
(soluble N-ethylmaleimide-sensitive factor attachment pro-
tein receptor) complex, which is the core process behind
synaptic vesicle (SV) fusion and exocytosis (Engel, Selcen,
Shen, Milone, & Harper, 2016; Shen, Selcen, Brengman,
& Engel, 2014; Shen et al., 2017).
Rabphilin 3a is an evolutionary conserved molecule that
interacts with the small GTP-binding proteins Rab3A and
Rab27a, and it participates in the trafficking and release of
both synaptic and secretory vesicles (Shirataki et al., 1993).
Rabphilin 3a consists of an N-terminal domain that binds
Rab3a and Rab27a, a linker region that binds 14-3-3, and
two tandem C2 domains that bind Ca2+ and phosphatidyli-
nositol 4,5-bisphosphate (PIP2) (Kato et al., 1996; Shirataki
et al., 1993; Sun, Bittner, & Holz, 2003) (Figure 1a). The
second C2 domain (C2B) also mediates specific interactions
with SNAP25 and CASK (Tsuboi & Fukuda, 2005). More-
over, similar C2 domains are found in several other mole-
cules that are also involved in SV trafficking, docking and
fusion, including synaptotagmin, Doc2, Munc13 and RIM
(Corbalan-Garcia & Gomez-Fernandez, 2014).
The precise role of rabphilin 3a in synaptic transmission
is complex and poorly understood. Deletion of the rabphi-
lin 3a gene (RPH3A) (OMIM 612159) in mice and
Caenorhabditis elegans resulted in no obvious phenotypic
effects (Schl€uter et al., 1999; Staunton, Ganetzky, & Nonet,
2001), but facilitated recovery of responses at depressed
synapses (Deak et al., 2006). Furthermore, microinjection
of exogenous rabphilin 3a inhibited SV exocytosis in squid
giant axons (Burns, Sasaki, Takai, & Augustine, 1998).
Together, this suggests that rabphilin 3a may act as a brake
on SV release in neurons. In contrast, overexpressing rab-
philin 3a enhanced hormonal release in bovine chromaffin
and PC12 cells, suggesting that it promotes exocytosis in
neuroendocrine cells (Chung, Takai, & Holz, 1995). Thus,
it seems that under different conditions rabphilin 3a can
exert either positive or negative effects on exocytosis and
downstream endocytosis (Deak et al., 2006).
We report here an individual with a mild form of CMS
and additional neurologic manifestations attributed to
mutations in the rabphilin RPH3A, in whom an electron
microscopy (EM) study of motor nerve terminals revealed
signs consistent with altered exocytosis and downstream
endocytosis.
2 | CLINICAL REPORT
The patient is an 11 year old girl, who was born full-term
to a nonconsanguineous couple and had an uncomplicated
perinatal period. All early motor milestones were achieved
on target, but during early childhood her parents noticed
limb weakness and poor physical endurance. At age 3 she
developed hand tremors, incoordination in hands and pos-
tural imbalance (Video S1). At age 5 she developed hyper-
nasal speech and a flexible laryngoscopy confirmed the
presence of velopharyngeal insufficiency. She also has his-
tory of recurrent abdominal pains and transient hyper-
glycemia. She had learning disabilities, particularly for
word reading, reading comprehension and spelling, but
brain MRI and EEG were normal. Repetitive stimulation of
the left spinal accessory and ulnar nerves revealed no
decrement of compound muscle action potential (CMAP)
amplitudes with stimulation at 2 Hz, but an increment of
30% of CMAP areas was noted with stimulation at 30 Hz.
Serum antibodies against AChR and MuSK were negative.
A biopsy of the right quadriceps muscle at age 6 and the
left anconeus muscle at age 8 revealed no significant
abnormalities at the light microscopy level. Single fiber
EMG by axonal stimulation in the right deltoid muscle per-
formed at the time of her anconeus biopsy revealed
increased jitter consistent with failure of neuromuscular
transmission. She had obstructive sleep apnea, which par-
tially subsided after tonsillectomy. A recent neurologic
examination revealed no dysmorphic features, and normal
behavior for age. She had no ptosis and normal external
ocular movements. She had mild weakness of neck flexors
and proximal muscles of the upper extremities with normal
deep tendon reflexes. Coordination testing revealed moder-
ate dyssynergia to finger-to-nose test and impaired rapid
alternating movements of hands. She had difficulties to per-
form tandem gait.
To investigate the nature of the neuromuscular deficit
part of the material from the anconeus muscle biopsy was
used for structural endplate studies, which included acetyl-
cholinesterase (AChE) reaction in teased muscle fibers,
alpha-bungarotoxin (aBGT) staining of endplates and EM
of the neuromuscular junction (NMJ). Light microscopy
showed only type I predominance; however, low magnifi-
cation EM revealed occasional myofibers with nonspecific
filament bodies and mild Z-disk disruption. The staining
with AChE and aBGT showed endplates of normal size
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and distribution with normal expression of AChE and
AChR (Figure S1 and Figure 1b).
The EM studies of the NMJs identified three distinct
changes: First, there was a reduction in the density of SVs,
but the average diameter of SVs in the patient’s muscle was
not different from controls (Figure 1c–d). Second, there was
an increase in nonvesicular synaptic membranes, including
abundant endosomes, coated pits and double-membrane
bound sacs (DMBS) containing SVs (Figure 1d–f). Third,
there were degenerative lamellar bodies (Figure 1e).
The morphometric analysis revealed that in comparison
to control anconeus muscles, the patient showed no reduc-
tion in postsynaptic folding expressed as the endplate index
(ratio of postsynaptic membrane length/presynaptic mem-
brane length) (Table S1). The average width of the primary
synaptic cleft and the average axon terminal area were also
normal.
3 | MATERIALS AND METHODS
To elucidate the genetic bases of the proband’s disease she
had a karyotype study, which showed a balanced transloca-
tion of part of the long arm of the X chromosome onto the
short arm of chromosome 11 [46,X, t(X;11)(q26.1;p15.3)],
but there was no significant rearrangements of nuclear or
mitochondrial DNA detected by a comparative genomic
hybridization microarray. Furthermore, no large deletions
or deleterious point mutations of mitochondrial DNA were
identified by next generation sequencing. Next, whole
exome sequencing (WES) was performed as described in
the Supporting Information Method Section and the vari-
ants of interest were confirmed by Sanger sequencing. The
study was approved by the institutional review board of the
University of California Davis and all participating individ-
uals signed a consent form.
a
c d
e f
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FIGURE 1 Rabphilin 3a domains and pathological findings: a. Schematic representation of rabphilin 3a showing the locations of the
variants and the most important sites of interactions with other proteins. The FYVE (or RBD) domain encompasses the Zn binding site for Rab3a
and the Arg269Gln variant lies adjacent to the binding site for 14-3-3. The Val464Leu variant is located in the C2A domain and the C2B
domain mediates binding to SNAP25. b. Endplate of the patient stained with rhodamine-aBGT demonstrating normal size and expression of
AChRs. c. Normal NMJ of a control patient. d. A NMJ of the patient showing severe depletion and variable shapes of SVs (black arrowheads
point to a coated SVs and oblique white arrows point to elliptic shaped SVs), abundant endosomes (oblique black arrows) and a DMBS
containing SVs (vertical black arrow). e. A NMJ showing a degenerative lamellar body (horizontal black arrow) and abundant endosomes. f. A
NMJ showing a DMBS containing SVs. The calibration mark represents 14 lm in B, 0.5 lm in c and d, and 0.8 lm in e and f
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4 | RESULTS
Analysis of WES revealed single nucleotide variants in
three genes with potential association with the phenotype
of the patient (Tables S2 and S3). The genes were ALG13
(OMIM 300776), DOK7 (OMIM 610285), and RPH3A.
ALG13 along with ALG14 (OMIM 612866) encodes the
UDP-GlcNAc transferase, which catalyzes a key step in
endoplasmic reticulum N-linked glycosylation Since muta-
tions in ALG14 have recently been reported in association
with CMS (Cossins et al., 2013) any rare sequence variant
in ALG13 was considered potentially relevant. The patient
was a carrier of a heterozygous c.1154 A>G change result-
ing in p.Glu385Gly in ALG13, which is a rare variant
[G = 0.0003/1 (1000 Genomes)]. However, the effect of
this variant that the patient inherited from her unaffected
mother is predicted to be tolerated by the SIFT and Poly-
Phen-2 programs. Furthermore, the phenotype associated
with mutations in ALG13 is one of epileptic encephalopa-
thy not present in either the patient or the mother, who
both carry the same sequence variation. Thus, Glu385Gly
in ALS13 was considered unlikely to be causative.
Both the patient and her unaffected mother were found
to be heterozygous for the DOK7 pathogenic mutation
1124_1127dupTGCC. However, Sanger sequencing failed
to detect a second mutation in the same gene. Nevertheless,
since intragenic microdeletions in DOK7 are possible, an
analysis of coding and untranslated regions of this gene
was performed using a high density DOK7-specific array,
which was also normal (Figure S2). Thus, since DOK7
myasthenia is recessive, the heterozygous mutation found
in this gene was also considered unlikely to be causative.
By contrast, given the implications of rabphilin 3a in
SV vesicle trafficking and neurotransmitter release, muta-
tions in RPH3A were considered relevant to the phenotype
of the patient.
The two variants identified in RPH3A by WES were
validated by Sanger sequencing and confirmed that each
one derived from each parent (Figure 2a). The paternally
inherited variant c.806 G>A, p.Arg269Gln (rs373497170)
is rare [A = 0.0008/50 (ExAC)], involves a nonconserva-
tive amino acid substitution of a residue that is conserved
among most species (Figure 2b) and is predicted to be
pathogenic by SIFT and PolyPhen-2 HumVar. The
p.Arg269Gln change is located in the linker region follow-
ing the Rab3A binding site (residues 70–140) and neigh-
bors Ser-272, which is the likely phosphorylated residue to
which 14-3-3 binds (Sun et al., 2003).
The maternally inherited variant c.1390 G>T, p.Val464-
Leu (rs35555961) is rare [T = 0.0007/84 (ExAC)] and
involves a conservative amino acid substitution of a residue
that is conserved across most species (Figure 2b). While
p.Val464Leu is predicted to be tolerated by SIFT and
PolyPhen-2HumVar it lays in the highly conserved fifth
beta strand of the C2A domain, which mediates binding of
Ca2+ and PIP2 (Coudevylle, Montaville, Leonov, Zweck-
stetter, & Becker, 2008).
To investigate the impact of p.Arg269Gln and p.Val464-
Leu we introduced them in a human RPH3A clone and stud-
ied the effect of the variants on binding to known partners,
including 14-3-3, Rab3a and SNAP25 (Supporting Informa-
tion Method Section). To assay 14-3-3 interaction, we
expressed the rabphilin 3a constructs in HEK cells by tran-
sient transfection, and then the solubilized cell lysates were
incubated ~ 1 hr with GST-14-3-3 eta fusion protein purified
on Glutathione 4B beads. After washing, rabphilin 3a protein
bound to the GST-14-3-3 beads was eluted and detected by
immunoblotting with anti-rabphilin 3a antibody. All rabphi-
lin 3a variants were expressed at similar levels in the cell
lysates and, as expected, we detected robust pulldown of rab-
philin 3a WT by GST-14-3-3 eta but not by GST control
beads (Figure 2c). Notably, pulldown of rabphilin 3a
p.Arg269Gln was severely reduced compared to wild type
(8  3% of WT levels; n = 4, p < 0.001, Student’s t-test),
whereas p.Val464Leu was only slightly reduced (66  20%
of WT levels; ns). Thus, rabphilin binding to 14-3-3 eta is
significantly impaired in the p.Arg269Gln variant.
To assay interaction with Rab3a and SNAP25, we co-
expressed these constructs together with rabphilin 3a-YFP
in HEK cells and defined their cellular localization via
immunofluorescence (Supporting Information Method Sec-
tion). Rabphilin 3a WT was diffusely distributed when
expressed alone but redistributed with Rab3a into vesicular
compartments when they were coexpressed. A similar
redistribution was observed with rabphilin 3a p.Arg269Gln
and p.Val464Leu, indicating that they also interact with
rab3a. In addition, both rabphilin 3a WT and p.Val464Leu
recruited SNAP25 to these compartments (Figure 2d).
Thus, the Val464Leu substitution in the C2A domain does
not significantly disrupt binding of rab3a to the amino-ter-
minus, or SNAP25 to the adjacent C2B domain.
5 | DISCUSSION
The condition described in this report expands the list of
presynaptic forms of CMS recently identified with the
assistance of WES. In comparison with postsynaptic forms,
the newly discovered presynaptic CMS are rarer and often
involve additional neurologic manifestations, including
developmental delay, seizures, tremors and ataxia, which
are not usually seen in postsynaptic CMS (Engel et al.,
2016; Shen et al., 2014). At the electrophysiological level
most of these presynaptic conditions show findings consis-
tent with the Lambert Eaton Myasthenic Syndrome
(LEMS). Moreover, in the few cases studied with
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intracellular microelectrodes, an impairment of the quantal
release of neurotransmitter was confirmed as the primary
mechanism of failure of neuromuscular transmission (Engel
et al., 2016; Shen et al., 2014).
While the increment of CMAP areas in response to
repetitive nerve stimulation at fast rates in our patient
suggested a LEMS-like condition, the characteristic decre-
ment of CMAP amplitudes with slow rates of stimulation
was not present, probably because the defect of transmis-
sion was mild and only detectable by single fiber EMG. In
this regard, the mild neuromuscular deficit of our patient is
in keeping with the modest phenotype that results from
FIGURE 2 Pedigree, alignment of variants and expression studies. a. Family tree showing the segregation of RPH3A variants. b. Sequence
alignments across species showing the location of the variants at conserved domains of the protein. c. Assay of rabphilin 3a–14-3-3 binding.
Rabphilin 3a (Rph3a) variants were expressed in HEK cells and the cell lysates incubated with GST or GST-14-3-3 eta beads. Rabphilin pulled
down on the beads was detected by immunoblotting with anti-rabphilin 3a antibody (upper panel) and GST-fusion proteins were detected by
Coomassie staining (lower panel). Control (c) is the cell lysates of sham-transfected cells. Rabphilin 3a pulldown by GST-14-3-3 eta was
severely reduced by the Arg269Gln mutant, but only marginally by Val464Leu compared to rabphilin 3a WT. d. Rabphilin 3a colocalization
with SNAP25. HEK cells transfected with rabphilin 3a-YFP, Rab3a and/or SNAP25 were immunostained with SNAP25 antibodies. When
expressed alone, SNAP25 was diffusely distributed, but when co-expressed it partially colocalized with rabphilin in vesicular bodies (yellow
puncta) near the cell membrane. Both rabphilin 3a WT and Val464Leu induced a similar redistribution of SNAP25. The calibration mark
represents 10 µm
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deletion of RPH3A in mice and Caenorhabditis elegans
(Schl€uter et al., 1999; Staunton et al., 2001).
In terms of the underlying pathogenic mechanism, it is
unlikely that the reported syndrome is due to the DOK7
1124_1127dupTGCC mutation paired with an unidentified
mutation in the same gene missed by direct sequencing and
by the DOK7 specific high density gene-centric array analy-
sis. Moreover, the phenotype linked to DOK7 mutations is
one of limb-girdle myasthenia (Palace et al., 2007), not obvi-
ous in our patient; and does not associate with central ner-
vous system symptoms, present in our patient. We cannot
discount the possibility, however, that the heterozygous
DOK7 1124_1127dupTGCC mutation acts as a genetic mod-
ifier that enhances the phenotype of the rabphilin mutations.
On the other hand, rabphilin 3a mutations are likely
causative since they could impair neuromuscular transmis-
sion by disrupting SV release and/or recycling. As rabphi-
lin 3a limits SV release (Burns et al., 1998; Deak et al.,
2006), exocytosis could be less restrained by rabphilin 3a
variants, ultimately leading to a depletion of SVs and fail-
ure in transmission. Alternatively, rabphilin 3a variants
could perturb SV recycling, which is essential to maintain
the vesicle pool. Indeed, injection of rabphilin 3a fragments
at the squid giant synapse both inhibited transmitter release
and reduced SV number by disrupting vesicle recycling
(Burns et al., 1998). This appears to involve multiple rab-
philin 3a domains and protein interactions as an NH2-term-
inal rabphilin 3a fragment impaired endocytosis from the
plasma membrane, while a C2A/B domain fragment dis-
rupted a later step in vesicle trafficking.
Our analysis revealed defects in the motor nerve termi-
nals of the patient consistent with this interpretation. In
addition to a marked reduction in the density of SVs, we
also observed DMBS, aberrant endosomes and degenerative
lamellar bodies, which all suggest altered vesicular traffick-
ing. Consequently, we propose that the rabphilin 3a vari-
ants impair one or more steps in SV recycling, such as
endocytosis or endosomal processing, and thereby reduce
the available vesicle pool and the efficiency of transmis-
sion. Potentially, this could occur by disrupting mecha-
nisms that regulate rabphilin 3a function, as Arg269Gln
lies adjacent to an activity-dependent phosphorylation site
(S272) that regulates 14-3-3 binding (Foletti & Scheller,
2001; Sun et al., 2003), and Val464Leu lies in the C2A
domain that is regulated by Ca2+.
Also of interest are the similarities between rabphilin 3a
and synaptotagmin 2, which is another molecule that con-
tains two C2 Ca2+/phospholipid binding domains. Synapto-
tagmin 2 can also have positive and negative effects on SV
release (Kochubey, Lou, & Schneggenburger, 2011), and
interacts directly with proteins associated with the SNARE
complex (Chapman, Hanson, An, & Jahn, 1995). More-
over, two different mutations in the C2B domain of
synaptotagmin 2 result in autosomal-dominant CMS, with
disrupted SV exocytosis (Herrmann et al., 2014). It is pos-
sible, therefore, that single allele mutations in RPH3A may
also result in disease. In fact, in our patient, we demon-
strate a clear pathogenic effect for the Arg269Gln variant,
whereas the effect of the Val464Leu variant remains
unknown. Thus, we cannot discount the possibility monoal-
lelic RPH3A variants causing autosomal-dominant CMS,
but with variable penetrance due to modifier effects from
other variants in the same or other genes.
In summary, we report a patient with a complex pheno-
type characterized by failure of neuromuscular transmis-
sion, tremors and learning disabilities whose motor nerve
terminals showed signs of disruptive SV homeostasis. The
condition is attributed to sequence variants in RPH3A that
alter both exocytosis and downstream endocytosis and SV
recycling. The condition shows a favorable response to
treatment with albuterol sulfate and encourages further
research on the role of rabphilin 3a in human neurologic
disorders of synaptic transmission.
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